Tonix Pharmaceuticals shares are trading higher after the company announced the issuance of a US patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines, with market exclusivity expected into 2036.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares rose following the announcement of a new US patent for the subcutaneous delivery of Zembrace Symtouch, a migraine treatment, with market exclusivity expected until 2036.
September 27, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock is up due to a new US patent for Zembrace Symtouch, a migraine treatment, granting market exclusivity until 2036.
The issuance of a US patent for Zembrace Symtouch provides Tonix Pharmaceuticals with market exclusivity until 2036, which is a significant competitive advantage. This development is likely to positively impact the company's stock price in the short term as it secures a long-term revenue stream from this product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100